OZG-3861

OZG-3861 is an experimental dendritic cell-based vaccine candidate developed by Acibadem Labcell for the prevention or treatment of COVID-19. The candidate is designed to target the SARS-CoV-2 spike (S) protein, a key component the virus uses to enter human cells. By priming dendritic cells with the spike protein, the therapy aims to stimulate a robust and specific T-cell mediated immune response against the virus. Developed by the Turkish cellular laboratory Acibadem Labcell, OZG-3861 represents an application of advanced immunotherapy techniques to address the global pandemic. As of the latest reports, the drug's clinical development status remains in the early stages with a pending phase designation.